Design for the Patient Experience
ICON is empowering patients, encouraging compliance, and easing the burden of participating in trials through its FIRECREST digital platform, backed by extensive research on behavioural decision-making and information technology.
Thanks to the web, community groups on social media (such as patient advocacy groups) and real-time access to physiological data from wearables and smartphone apps, patients can be better informed than they ever have been.
Identifying and addressing unmet patient needs is, and always will be, the ultimate goal of pharmaceutical R&D. Therefore, new clinical trial models and the technologies behind them should be harnessed to achieve those goals. In many cases, technology that allows constant monitoring of, and communication with, patients in real time creates the possibility to assess the results of therapies at a level of granularity and over a range of real-world conditions never before imagined – and to intervene in real time if necessary to improve patients’ lives.
The culture of clinical research is evolving from one directed by researchers to one driven by the needs of patients and those who care for them. Among the possibilities for making trials more responsive to patient needs are:
These topics are discussed in detail in our industry survey and whitepaper 'Improving Pharma R&D Efficiency'
Thanks to the web, community groups on social media (such as patient-advocacy groups) and real-time access to physiological data from wearables and smartphone apps, patients can be better informed than they ever have been.
Leveraging Voice-Assistant Technology in Clinical Trials
ICON is working with the International Consortium for Health Outcomes Measurement (ICHOM) to develop The Global Outcomes Benchmarking (GLOBE) program. Rather than focusing on clinical indicators, ICHOM shifts the focus to outcomes that patients care about, including functional improvements and the capacity to live productive lives.
Continuous monitoring of patients enables continuous treatment adjustments and alerts clinicians when emergencies arise - resulting in better, more personalised treatment and improved clinical outcomes, with fewer clinic visits and greater independence for patients.
Patient Centric Monitoring is ICON’s methodology for the design and execution of an adaptive risk based monitoring strategy guided by risk assessment using ICONIK analysis. Risk based monitoring in clinical trials is a monitoring approach where activities, resources and technologies are adapted to the risks in the study. Patient Centric Monitoring further focuses on the probability of errors that matter in decision making for patients.
Today, fewer and fewer patients passively accept physicians’ advice. Patients are increasingly active, informed consumers entering clinics armed with research and opinions about their healthcare options. They desire data on similar patients while calculating the benefits and risks of their choices. To the patient–consumer, "precision medicine" represents the ideal standard of care: the individualised, evidence-based treatment that provides the best opportunity for a positive outcome. Read our three-part series exploring the patient-consumer:
Part One: From Biomarkers to Biosensors
Many patients with serious diseases cannot wait for an investigational product to move from the lab to the pharmacy shelf. Managed Access Programs are one solution for early access to investigational products. Read our whitepaper to prepare for the clinical and operational complexities.
Registries are economical and flexible, and ideal for collecting data from a wide range of patients and sites, generating the real world evidence regulators and payers require to demonstrate effectiveness and safety, and to support label and coverage extensions. But this flexibility also creates risk. To generate useable, uniform data, registries must be carefully designed and administered. Consider these seven factors as you design and launch a successful registry.